Surgeries & Interventions July 25, 2024
Magenta Medical Adds $105M, Targets MCS Disruption July 25, 2024
Israeli heart pump startup Magenta Medical wrapped up a $105M financing round to advance clinical programs supporting its Elevate left ventricular assist device, a percutaneous heart pump that Magenta believes could disrupt the mechanical circulatory support segment.
Patient Engagement July 22, 2024
The Psychological Impact of AFib Wearables July 22, 2024
AFib patients are increasingly using consumer wearable devices for symptom monitoring, but a new JAHA study suggests that these devices' often-publicized healthcare benefits are offset by their negative impacts on patient anxiety and healthcare overuse.
Pharmaceuticals July 18, 2024
Lexeo LX2006 Shows Promise for Friedreich’s Ataxia Cardiomyopathy July 18, 2024
Lexeo Therapeutics gave the 5,000 Americans with Friedreich’s ataxia cardiomyopathy reason for optimism, publishing early results that suggest its LX2006 gene therapy could be able to treat FA cardiomyopathy.
Surgeries & Interventions July 15, 2024
Baylor St. Luke’s Settles Concurrent Cardiac Surgery Case July 15, 2024
Cardiac surgeon compensation is generally a numbers game - the more procedures you do, the more you make. However, a Medicare fraud settlement featuring some of Houston’s most prominent institutions and cardiac surgeons reveals the pitfalls of this incentive structure.
Population Health July 11, 2024
Nearly Half of American Counties Don’t Have Cardiologists July 11, 2024
A new JACC study found that 46.3% of U.S. counties don’t have a single cardiologist, meaning that the 22M people who live in these "cardiology desert" countries have to drive an average of 90 miles round trip to see their cardiologist.
Structural Heart July 8, 2024
Older Patients and Asymptomatic Valvular Heart Disease July 8, 2024
A new study out of the UK found that over a quarter of people aged 60+ have asymptomatic valvular heart disease, and revealed that prevalence increases as patients age -- potentially providing new reasons to screen older patients for VHD.
Cardiology July 1, 2024
Cardiology in H1 2024 July 1, 2024
The first half of 2024 is now a wrap, and it was another big one in cardiology. Here are some of Cardiac Wire’s top six storylines from the last six months, plus some things to keep in mind as we head into 2024’s second half.
Surgeries & Interventions June 27, 2024
Shockwave Therapy’s Ischemic Heart Failure Potential June 27, 2024
New research out of Austria suggests that cardiac shockwave therapy could help address ischemic heart failure patients’ myocardial regeneration challenges, allowing meaningful LVEF and quality of life improvements, and potentially better outcomes.
Artificial Intelligence June 24, 2024
New Echo AI Model Could Streamline Mitral Regurgitation Diagnosis June 24, 2024
Columbia and Cornell researchers developed an echo AI model that could improve the difficult task of mitral regurgitation diagnosis, and might even represent an AI-driven step towards enhancing all valvular regurgitation assessments.
Pharmaceuticals June 20, 2024
Marea Therapeutics’ Cardiometabolic Mission June 20, 2024
Marea Therapeutics emerged this week, announcing $190M in Series A/B funding and a mission to develop "a new generation of medicines for cardiometabolic diseases" - starting with their drug candidate targeting remnant cholesterol.
Cardiology Practices June 17, 2024
The Rise of Private Equity Cardiology Practice Acquisitions June 17, 2024
New research in JAMA highlighted the rapid growth of private equity-backed cardiology practice acquisitions, while revealing some interesting geographic factors driving this growth.
Preventive Cardiology June 13, 2024
New Calculations Could Slash Statin-Eligible Population June 13, 2024
A JAMA paper suggests that if the CVD guidelines adopt the AHA’s new PREVENT cardiovascular risk equations, it might slash the US’s eligible preventive statin user population by nearly 40%.
Structural Heart June 10, 2024
Edwards’ Strong Five-Year Small Annulus TAVR Outcomes June 10, 2024
Edwards and Medtronic’s fight for TAVR supremacy took an interesting turn last week, after Edwards showed that its SAPIEN 3 valve has similar five-year outcomes among patients with both small and large aortic annulus, regardless of their mean gradients and rates of prothesis-patient mismatch.
Artificial Intelligence June 6, 2024
Philips Expands & Integrates Echo AI Platform June 6, 2024
Philips’ ultrasound AI strategy took another big step this week, with the launch of its next-generation echo AI platform, which will come integrated with the company’s cardiovascular ultrasound systems and bring a range of new echo-automating capabilities.
Preventive Cardiology June 3, 2024
Preventive Statins Safe & Effective in Older Patients June 3, 2024
There is little consensus on whether or when to use statins for primary CVD prevention in older patients, but a new study provides compelling evidence for expanding statin use in this population.
Cardiology Practices May 30, 2024
The Disappearance of Private Practice Cardiology May 30, 2024
In the not too distant past, the vast majority of cardiologists worked their entire careers in private practice, but a range of economic and administrative changes have driven around 70% of US cardiologists into hospital and corporate employment. In today’s issue, we’re diving into cardiology’s employment shift, and what the future holds for private practice cardiologists.
Electrophysiology May 23, 2024
Cardiac Wire’s Top Six Takeaways from HRS 2024 May 23, 2024
The HRS 2024 meeting is now complete, after over 9,500 electrophysiology professionals converged in Boston to witness EP medicine evolve in front of their eyes. Among dozens of highlights, here are the Cardiac Wire’s six biggest trends emerging from HRS24.
Artificial Intelligence May 20, 2024
AI Clearances Surge, Cardio AI Share Declines May 20, 2024
The FDA published its latest Healthcare AI Database last week, featuring a massive 882 AI-enabled medical device clearances, and highlighting some interesting trends in cardiovascular AI.
Heart Failure May 16, 2024
Aficamten Shines in SEQUOIA-HCM Trial May 16, 2024
Cytokinetics’ obstructive hypertrophic cardiomyopathy drug aficamten excelled in its SEQUOIA-HCM Phase 3 trial, significantly improving peak oxygen uptake, while achieving all secondary effectiveness and safety endpoints.
